At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Docetaxel for Metastatic Prostate Cancer. Completed, enrolled 49 participants across 5 sites.
Detailed Summary
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartJul 2007
Primary CompletionFeb 2012
Study CompletionJan 2013
TodayJul 2026
First PostedFeb 23, 2007
Enrollment StartJul 1, 2007
Primary CompletionFeb 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.4 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
Docetaxeldrug
Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.